

Singapore approves GSK's new cancer therapy for ovarian cancer

July 4, 2022 | News

For first-line and recurrent monotherapy maintenance treatment in advanced ovarian cancer



GlaxoSmithKline (GSK) Singapore has announced that Health Sciences Authority has approved *Zejula* (niraparib) tablet, an oral, once-daily first-line and recurrent maintenance treatment for women with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response following platinum-based chemotherapy.

This new product registration makes *Zejula* the only poly (ADP-ribose) polymerase (PARP) inhibitor approved in Singapore for use as a monotherapy for patients with advanced and recurrent ovarian cancer, regardless of whether they have *BRCA* mutation.

Zejula is available for first-line ovarian cancer (PRIMA) in 44 countries and 2 Special Administrative Regions as of March 2022. *Zejula* is also being assessed across multiple tumour types and evaluated in combinations with several other therapeutics. Notably, it is currently being tested in a Phase III clinical trial, ZEST, exploring its further potential in treating patients with triple-negative breast cancer (TNBC) or *BRCA* or HER2- breast cancer, mutations which require specialised treatment.